| Literature DB >> 33930998 |
Joyce Oloaigbe Ogidigo1,2, Chioma Assumpta Anosike1, Parker Elijah Joshua1, Collins U Ibeji3, Daniel Emmanuel Ekpo1, Bennett C Nwanguma1, Okwesili Fred Chiletugo Nwodo1,4.
Abstract
CONTEXT: Bryophyllum pinnatum (Lam.) Oken (Crassulaceae) is used traditionally to treat many ailments.Entities:
Keywords: Alzheimer’s diseases; acetylcholinesterase; butyrylcholinesterase; carlinoside; docking studies; lipid peroxidation
Mesh:
Substances:
Year: 2021 PMID: 33930998 PMCID: PMC8871626 DOI: 10.1080/13880209.2021.1913189
Source DB: PubMed Journal: Pharm Biol ISSN: 1388-0209 Impact factor: 3.503
Figure 1.Bryophyllum pinnatum plant.
Constituents of BPFRF identified and characterized by UPLC-PDA-Q/TOF-MS2 analysis.
| Peaks |
|
| am/z | bM-H− | cMSE(MS/MS) |
|
|
|---|---|---|---|---|---|---|---|
|
| 18.56 | 221, 348 | 579.1341 | C26H27O15 | 151, 178,243, 255,271, 300,315,447 | 0.27 |
|
|
| 22.54 | 255, 370 | 301.0327 | C15H9O7 | 107,151,178,190,245,273 | 13.34 |
|
|
| 25.50 | 263, 367 | 285.0374 | C15H9O6 | 107,121,151,178,187,229,257 | 2.01 |
|
|
| 26.03 | 254,370 | 315.0477 | C16H11O7 | 107,148,151,164,178,227,255,277 | 3.49 |
|
|
| 26.33 | – | 327.2107 | C18H31O5 | 127,151,171,183,211,229,239,291, 300, 301,315 |
|
|
|
| 27.24 | 221,367 | 329.1502 | C18H33O5 | 127,151,171,183,211,229,233,251,300, 301 |
|
|
|
| 28.32 | 222.41 | 447.2006 | C24H31O8 | 89, 151,202, 216, 241, 285, 301, 311, 351, 379 | 0.92 |
|
|
| 29.74 | 223.49 | 795.4507 | C42H67O14 | 119,183,236,301,339, 457, 507, 615, 647, 691, 765 |
|
|
|
| 31.07 | No UV | 633.3901 | C36H57O9 | 85, 113, 116,151, 183, 220, 301, 339, 407, 463, 485, 559 |
|
|
|
| 32.45 | No UV | 293.2134 | C18H29O6 | 98, 116, 119, 121, 169, 171, 183, 235, 236,275 |
|
|
|
| 33.11 | No UV | 617.4011 | C36H57O8 | 85, 113, 151, 235, 253, 277, 339, 367,439, 497, 513, 579 |
|
|
|
| 34.15 | 226 | 265.1402 | C15H21O4 | 98, 116, 151, 183, 220, 255, 279 |
|
|
|
| 35.81 | 271.2201 | C13H27O8 | 130, 150, 171, 183, 197,221, 220, 226, 255, 235 |
|
| |
|
| 37.05 | 226 | 271.2214 | C13H27O8 | 96, 98, 100, 119, 139, 183, 199, 255, 265, 293, 325, 353, 397, 465 |
|
|
|
| 37.05 | 226 | 325.1812 | C14H29O8 | 79, 96, 119, 170, 183, 184, 197, 227, 265,293 |
|
|
aAccurate mass detection; bnegative ions; cmass fragmentation patterns with intensity normalised to 100 for the highest fragment. Rt: Retention time; λmax: maxima absorbance.
Figure 2.Overlay of UPLC chromatogram at 280 nm top and base peak intensity (BPI) chromatograms (bottom) of BPFRF.
Figure 3.Photodiode array detector (PDA) spectra and mass spectra (MS/MS) fragmentation pattern present in B. pinnatum flavonoid-rich fraction (BPFRF). Luteolin C-glucoside-C-arabinoside (carlinoside) (A). Quercetin (B). Luteolin (C). Quercetin-3-methyl ether (isorhamnetin) (D). Luteolin-7-glucoside (E).
Figure 4.2,2-Diphenyl-1-picrylhydrazyl free radical scavenging effect of BPFRF in comparison with ascorbic acid (3.125–100 μg/mL).
DPPH radical scavenging potential, lipid peroxidation inhibitory activity and cholinesterase inhibitory activity of BPFRF, quercetin and standards.
| Samples | DPPH radical IC50 (µg/mL) | Lipid peroxidation IC50 (µg/mL) | AChE IC50 (µg/mL) | BuChE IC50 (µg/mL) |
|---|---|---|---|---|
| BPFRF | 7.382 ± 0.79 | 7.182 ± 0.60 | 22.283 ± 0.27 | 33.437 ± 1.46 |
| Ascorbic acid | 10.186 ± 0.14 | 14.393 ± 0.54 | ||
| Quercetin | 13.803 ± 0.34 | 25.242 ± 1.97 | 15.528 ± 0.08 | 24.326 ± 0.40 |
| Rivastigamine | 7.994 ± 0.12 | 20.120 ± 0.72 |
Figure 5.Fe2+-induced lipid peroxidation inhibitory activity of BPFRF and the ascorbic acid.
Figure 6.Cholinesterase inhibitory activity of BPFRF AChE (A). BuChE (B).
Binding energies of BPFRF ligands and known inhibitors against AChE and BuChE drug targets.
| Compound name | PubChem ID | Chemical formula | Binding affinity (kcal/mol) AChE | Binding affinity (kcal/mol) BuChE |
|---|---|---|---|---|
| Luteolin-7-glucoside* | 5280637 | C15H10O6 | −14.9 | −9.8 |
| Luteolin* | 5280445 | C15H10O6 | −12.3 | −7.4 |
| Quercetin* | 5280343 | C16H12O8 | −11.2 | −7.8 |
| Isorhamnetin* | 5281654 | C9H8O3 | −10.5 | −7.4 |
| Carlinoside* | 442584 | C9H10O5 | −8.9 | −12.7 |
| Rivastigmine# | 77991 | C28H48O | −10.4 | −6.9 |
#Known inhibitors; *Putative BPFRF inhibitors.
Figure 7.Illustrations of molecular interactions (left: 3D and right: 2D) between the/highest binding energies of BPFRF constituents and standard against AChE target. Luteolin-7-glucoside (red) (Ai, Aii). Quercetin (orange) (Bi, Bii). Rivastigmine (purple) (Ci, Cii).
Figure 8.Illustrations of molecular interactions (left: 3D and right: 2D) between the highest binding energies of BPFRF constituents and standard against BuChE target. Carlinoside (yellow) (Ai, Aii). Quercetin (grey) (Bi, Bii). Rivastigmine (purple) (Ci, Cii).